Clinical Drug Investigation

Papers
(The H4-Index of Clinical Drug Investigation is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe Toxicity63
First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treat57
Acknowledgement to Referees51
Comparison of the Incidence of Adverse Events Between Japanese and Non-Japanese Healthy Subjects in Phase I Studies: A Systematic Review and Meta-Analysis31
Guanfacine Use in the ICU for Management of Sedation Weaning27
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson’s Disease: A Systematic Review and Meta-Analysis26
Correction to: AVT04: An Ustekinumab Biosimilar25
Correction to: PB006: A Natalizumab Biosimilar24
AVT02: An Adalimumab Biosimilar22
Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study21
Antibiotic-Associated Acute Kidney Injury Among Older Adults: A Case-Crossover Study20
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment20
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers18
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study17
Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy17
Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, P17
Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz®) in Europe: A Prescriber Survey17
Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS17
0.16280794143677